Jesús Avila Selected Research

Glycogen Synthase (Synthase I)

1/2014	GSK-3β, a pivotal kinase in Alzheimer disease.
1/2014	New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease.
5/2010	Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
1/2010	Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
1/2009	Memantine inhibits calpain-mediated truncation of GSK-3 induced by NMDA: implications in Alzheimer's disease.
4/2008	Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease.
6/2007	Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice.
12/2006	Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
5/2006	Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3.
1/2004	Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jesús Avila Research Topics

Disease

86	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 10/2001
26	Tauopathies 01/2022 - 03/2002
23	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 12/2001
13	Neuroblastoma 01/2021 - 03/2002
13	Amyloid Plaque 10/2020 - 02/2002
9	Frontotemporal Dementia (Semantic Dementia) 01/2018 - 05/2004
9	Dementia (Dementias) 11/2017 - 12/2005
5	Cognitive Dysfunction 01/2018 - 01/2007
5	Huntington Disease (Huntington's Disease) 08/2014 - 12/2003
4	Mood Disorders (Mood Disorder) 05/2010 - 06/2004
3	Ganglion Cysts (Ganglion) 02/2012 - 05/2003
3	Gliosis 05/2006 - 12/2002
2	Neuroinflammatory Diseases 01/2022 - 10/2020
2	Nervous System Diseases (Neurological Disorders) 01/2014 - 10/2004
2	Pick Disease of the Brain (Pick's Disease) 01/2013 - 11/2005
2	Inflammation (Inflammations) 01/2010 - 01/2007
2	Brain Diseases (Brain Disorder) 08/2008 - 07/2002
2	Prion Diseases (Transmissible Spongiform Encephalopathies) 08/2008 - 05/2003
2	Parkinsonian Disorders (Parkinsonism) 12/2006 - 10/2002
2	Parkinson Disease (Parkinson's Disease) 10/2005 - 10/2002
2	Pathologic Processes 06/2005 - 03/2002
1	Brain Ischemia (Cerebral Ischemia) 12/2020
1	Paralysis (Palsy) 01/2019
1	Proteostasis Deficiencies 01/2018
1	Mitochondrial Diseases (Mitochondrial Disease) 08/2014
1	Seizures (Absence Seizure) 10/2013
1	Corticobasal Degeneration 01/2013
1	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 01/2013
1	Premature Aging 01/2013
1	Neoplasms (Cancer) 01/2011
1	Autoimmune Diseases (Autoimmune Disease) 01/2011
1	Schizophrenia (Dementia Praecox) 01/2011

Drug/Important Bio-Agent (IBA)

36	tau Proteins (tau Protein)IBA 01/2022 - 12/2001
24	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2002
19	Glycogen Synthase Kinase 3IBA 01/2014 - 05/2003
15	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2018 - 03/2002
12	Amyloid beta-PeptidesIBA 01/2017 - 02/2002
12	Glycogen Synthase (Synthase I)IBA 01/2014 - 06/2002
10	Amyloid (Amyloid Fibrils)IBA 10/2020 - 06/2002
8	Pharmaceutical PreparationsIBA 11/2017 - 06/2004
8	LithiumIBA 05/2010 - 06/2002
8	Glycogen Synthase Kinase 3 betaIBA 04/2008 - 12/2002
7	EnzymesIBA 01/2021 - 06/2002
7	Peptides (Polypeptides)IBA 10/2020 - 06/2002
6	Phosphotransferases (Kinase)IBA 01/2022 - 01/2004
5	Protein Isoforms (Isoforms)IBA 12/2020 - 03/2008
3	AcetylcholinesteraseIBA 01/2021 - 01/2011
3	PrionsIBA 03/2018 - 07/2002
3	N-Methylaspartate (NMDA)IBA 01/2017 - 01/2009
3	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2015 - 10/2010
3	Retinaldehyde (Retinal)IBA 02/2012 - 05/2003
3	Glycogen Synthase KinasesIBA 05/2010 - 11/2007
3	cortistatinIBA 01/2010 - 01/2007
3	AntibodiesIBA 01/2006 - 12/2003
3	UbiquitinIBA 01/2004 - 10/2002
2	Prion ProteinsIBA 01/2019 - 07/2002
2	Messenger RNA (mRNA)IBA 08/2017 - 08/2014
2	NucleotidesIBA 01/2017 - 01/2014
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2017 - 01/2009
2	NeuropeptidesIBA 01/2012 - 01/2007
2	Okadaic AcidIBA 09/2011 - 03/2002
2	Protein AggregatesIBA 08/2010 - 08/2008
2	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2010 - 08/2008
2	CalpainIBA 01/2009 - 08/2007
2	beta CateninIBA 06/2007 - 12/2002
2	QuinonesIBA 06/2005 - 03/2004
2	Insulin (Novolin)FDA Link 11/2004 - 05/2003
2	PolymersIBA 05/2004 - 10/2001
2	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2004 - 12/2003
2	GlycosaminoglycansIBA 07/2002 - 05/2002
1	p38 Mitogen-Activated Protein KinasesIBA 01/2022
1	Apolipoproteins E (ApoE)IBA 10/2020
1	Biomarkers (Surrogate Marker)IBA 09/2020
1	Peripheral Nervous System AgentsIBA 01/2019
1	MicroRNAs (MicroRNA)IBA 01/2018
1	oleuropein aglyconeIBA 01/2018
1	PolyphenolsIBA 01/2018
1	Olive OilIBA 01/2018
1	Cytoskeletal ProteinsIBA 01/2017
1	Flavin-Adenine Dinucleotide (FAD)IBA 01/2017
1	NexusIBA 01/2017
1	Presenilin-1IBA 01/2017
1	Small Interfering RNA (siRNA)IBA 06/2015
1	N-Methyl-3,4-methylenedioxyamphetamine (MDMA)IBA 08/2014
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 04/2014
1	DNA (Deoxyribonucleic Acid)IBA 01/2014
1	Pentylenetetrazole (Metrazol)IBA 10/2013
1	lucifer yellowIBA 06/2013
1	AntioxidantsIBA 01/2013
1	LaminsIBA 01/2013
1	NocodazoleIBA 01/2013
1	CaspasesIBA 11/2010
1	tau-protein kinaseIBA 01/2010
1	Neprilysin (Neutral Endopeptidase)IBA 01/2010
1	NeurotensinIBA 01/2010
1	Glucose (Dextrose)FDA LinkGeneric 01/2010

Therapy/Procedure

4	Therapeutics 04/2014 - 09/2006
2	Injections 10/2013 - 06/2013
1	Mediterranean Diet 01/2018
1	Institutionalization (Institutionalized Persons) 11/2017